Affinity Stabilization of Protein Drugs

Back to all technologies
Download as PDF
65558
The development of protein drugs is often hindered by the instability of these large, complex molecules.

Researchers at Purdue University have developed a novel method for stabilizing protein drugs based on ligand binding. The peptide epitopes are covalently linked to a biodegradable synthetic polymer, forming a pseudo-ligand. The pseudo-ligand binds to the protein drug with high affinity and helps to preserve near-native conformation, minimize unfolding, and prevent aggregation during manufacturing, shipping, and storage. Since the pseudo-ligand is comprised of a biodegradable polymer backbone and small peptide epitopes, it is expected to be biocompatible and nonimmunogenic. In some applications, it may be desirable to administer the protein drug in its free form. In such cases, the pseudo-ligand can be immobilized on a solid surface through a coupling agent and released prior to administration using a competing ligand.

Advantages:
-Preserves near-native conformation
-Biocompatible and nonimmunogenic

Potential Applications:
-Pharmaceutical industry

Related Publications:
Zhang, Jun, et al. Protein G, Protein A and Protein A-Derived Peptides Inhibit the Agitation Induced Aggregation of IgG. Molecular Pharmaceutics. 2012, 9 (3), pp 622–628.
DOI: 10.1021/mp200548x.
Mar 4, 2016
CON-Patent
United States
10328148
Jun 25, 2019

Oct 19, 2012
NATL-Patent
United States
(None)
(None)

Apr 22, 2011
PCT-Patent
WO
(None)
(None)

Apr 23, 2010
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org